Kollmann Karoline, Heller Gerwin, Sexl Veronika
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria. Karoline.
Oncotarget. 2011 May;2(5):422-7. doi: 10.18632/oncotarget.279.
A novel way by which the AP-1 factor c-JUN interferes with tumorigenesis has recently been elucidated [1]. In a model of murine leukemia, c-JUN prevents the epigenetic silencing of the cell cycle kinase CDK6. In the absence of c-JUN, CDK6 is down-regulated and the 5’region of the gene is methylated. Down-regulation of CDK6 results in significantly delayed leukemia formation. Here we show that c-JUN is also involved in protecting the promoter region of the tumor suppressor p16(INK4a), which is consistently methylated over time in c-JUN deficient cells. In cells expressing c-JUN, p16(INK4a) promoter methylation is a less frequent event. Our study unravels a novel mechanism by which the AP-1 factor c-JUN acts as a “bodyguard”,and preventing methylation of a distinct set of genes after oncogenic transformation.
最近阐明了一种AP-1因子c-JUN干扰肿瘤发生的新方式[1]。在小鼠白血病模型中,c-JUN可防止细胞周期激酶CDK6的表观遗传沉默。在缺乏c-JUN的情况下,CDK6被下调,基因的5'区域发生甲基化。CDK6的下调导致白血病形成显著延迟。在此我们表明,c-JUN还参与保护肿瘤抑制因子p16(INK4a)的启动子区域,在c-JUN缺陷细胞中,该区域会随着时间的推移持续发生甲基化。在表达c-JUN的细胞中,p16(INK4a)启动子甲基化的情况较少见。我们的研究揭示了一种新机制,即AP-1因子c-JUN作为“保镖”,在致癌转化后防止一组特定基因发生甲基化。